Europe Biosimilar Market 2025-2033
According to IMARC Group's report titled "Europe Biosimilar Market Report by Molecule (Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab), Indication (Auto-Immune Diseases, Blood Disorder, Diabetes, Oncology, Growth Deficiency, Female Infertility), Manufacturing Type (In-house Manufacturing, Contract Manufacturing), and Country 2025-2033", the report presents a thorough review featuring the market share, growth, share, trends, and research of the industry.
How Big is the Europe Biosimilar Industry?
The Europe biosimilar market size reached USD 13,864 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 59,733.3 Million by 2033, exhibiting a growth rate (CAGR) of 17.1% during 2025-2033.
Europe Biosimilar Market Trends:
The European market is primarily driven by growing demand for low-cost treatment options, primarily driven by patients with chronic illnesses. In support of this idea, the increasing prevalence of biologic drugs nearing patent expiration is increasing the availability of biosimilars. Additionally, the improving health care infrastructure across the region is allowing for better uptake of biosimilars supported by regulatory policies. Furthermore, increasing health care expenditures in Europe are allowing both patients and providers to consider biosimilars as a viable option.
Moreover, the growing focus on lowering overall health care expenditures is driving better uptake and growth of biosimilars, as they provide a significant savings opportunity without sacrificing treatment efficacy. In addition, increasing support from government and health organizations regarding biosimilar development will be an important factor driving growth in the market. Moreover, increasing awareness campaigns regarding safety and efficacy of biosimilars will help to grow acceptance of the drugs by patients and health care professionals. Furthermore, growing investments by pharmaceutical companies into biosimilar research and development will continue foster growth in the biosimilars market as they create competition and innovation for the drugs.
For an in-depth analysis, you can refer free sample copy of the report: https://www.imarcgroup.com/europe-biosimilar-market/requestsample
Europe Biosimilar Market Scope and Growth Analysis:
The market spectrum is greatly expanding due to more therapeutic applications, such as in oncology, immunology, and endocrinology, that fulfill unmet clinical needs. The progressing uptake of biosimilars in hospital settings facilitates their adoption into the mainstream treatment pathways of the market. Furthermore, the increasing availability of competitively priced biosimilar medicaments is helping improve access to sophisticated therapies, particularly in developing economies in Europe. Furthermore, the positive coupling of regulatory bodies and pharmaceutical companies is leading to an expedited approval and expedited market entry of products.
The increase in local manufacturing is additionally contributing to market diversification and addressing regional preferences. Furthermore, the introduction of advanced manufacturing techniques allows increase production output, lower costs, and aid in the overall supply chain. Additionally, the increasing focus on biosimilars interchangeability provides ren exclusively to prescribers, strengthening market acceptance and awareness. Also, according to market observations, the changing reimbursement landscape in support of biosimilars is enhancing the market outlook due to a more favourable market for players and healthcare systems.
Ask Analyst For Customization: https://www.imarcgroup.com/request?type=report&id=1023&flag=C
By the IMARC Group, the Top Competitive Landscapes Operating in the Industry:
- Novartis
- Pfizer
- Teva
- Celltrion
- Merck Sharp & Dohme
- Samsung Bioepis
- Eli Lilly
- Accord Healthcare Ltd.
- Amgen
- Boehringer Ingelheim
- Hexal Ag
- Apotex
- Stada Arzneimittel Ag
- Ratiopharm
- Mylan
Europe Biosimilar Market Segmentation:
The market report offers a comprehensive analysis of the segments, highlighting those with the largest Europe biosimilar market share. It includes forecasts for the period 2025-2033 and historical data from 2019-2024 for the following segments.
Breakup by Molecule:
- Infliximab
- Insulin Glargine
- Epoetin Alfa
- Etanercept
- Filgrastim
- Somatropin
- Rituximab
- Follitropin Alfa
- Adalimumab
Breakup by Indication:
- Auto-Immune Diseases
- Blood Disorder
- Diabetes
- Oncology
- Growth Deficiency
- Female Infertility
Breakup by Manufacturing Type:
- In-house Manufacturing
- Contract Manufacturing
Breakup by Country:
- Italy
- Germany
- United Kingdom
- France
- Spain
- Rest of Europe
Key highlights of the Report:
- Market Performance (2019-2024)
- Market Outlook (2025-2033)
- COVID-19 Impact on the Market
- Porter’s Five Forces Analysis
- Strategic Recommendations
- Historical, Current and Future Market Trends
- Market Drivers and Success Factors
- SWOT Analysis
- Structure of the Market
- Value Chain Analysis
- Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
Comments
0 comment